Creating new hope and better patient insights through precision diagnostics and therapeutics
Portfolio Development Overview
2022
H1
H2
2023
H1
H2
2024
H1
H2
Dengue (mAb)
Pre-Clinical (in vitro)
Pre-Clinical (in vivo)
Clinical Trial (Phase I)
H2
Clinical Trial (Phase II)
Dengue (GENIE)
Prototype Development
Sales (Research Use Only)
Sales (Regulatory Approved)
COVID (Imtracker)
RUO Usage
Regulatory approvals
TB Therapeutic
Pre-Clinical (in vitro)
Portfolio Development Overview
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Massa, ac tristique erat sed porta. Cursus nam quam convallis enim erat id euismod. Blandit nam massa tempus,
